Natsumi Tsuboyama
Overview
Explore the profile of Natsumi Tsuboyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang T, Beytullahoglu O, Tulaiha R, Luvisotto A, Szczepanski A, Tsuboyama N, et al.
J Clin Invest
. 2025 Jan;
135(2.
PMID: 39817454
Mutations or homozygous deletions of MHC class II (MHC-II) genes are commonly found in B cell lymphomas that develop in immune-privileged sites and have been associated with patient survival. However,...
2.
Tanimoto S, Sone K, Jonouchi Y, Hachijo R, Suzuki E, Tsuboyama N, et al.
Oncol Lett
. 2024 Dec;
29(3):106.
PMID: 39736925
Although ovarian endometrioid carcinoma (OEC), frequently associated with endometrial endometrioid carcinoma (EEC), is often diagnosed at an early stage, the prognosis remains poor. The development of new, effective drugs to...
3.
Szczepanski A, Tsuboyama N, Lyu H, Wang P, Beytullahoglu O, Zhang T, et al.
Nat Commun
. 2024 Mar;
15(1):2067.
PMID: 38453939
Recent studies have identified a previously uncharacterized protein C11orf53 (now named POU2AF2/OCA-T1), which functions as a robust co-activator of POU2F3, the master transcription factor which is critical for both normal...
4.
Inoue F, Sone K, Kumegawa K, Hachijo R, Suzuki E, Tanimoto S, et al.
Int J Oncol
. 2024 Feb;
64(3).
PMID: 38299254
Histone modification, a major epigenetic mechanism regulating gene expression through chromatin remodeling, introduces dynamic changes in chromatin architecture. Protein arginine methyltransferase 6 (PRMT6) is overexpressed in various types of cancer,...
5.
Runge M, Richardson R, Clay P, Bell A, Holden T, Singam M, et al.
PLOS Glob Public Health
. 2023 Mar;
2(5):e0000308.
PMID: 36962179
In non-pharmaceutical management of COVID-19, occupancy of intensive care units (ICU) is often used as an indicator to inform when to intensify mitigation and thus reduce SARS-CoV-2 transmission, strain on...
6.
Szczepanski A, Tsuboyama N, Watanabe J, Hashizume R, Zhao Z, Wang L
Sci Adv
. 2022 Oct;
8(40):eabq2403.
PMID: 36197978
Small cell lung cancer (SCLC), accounting for around 13% of all lung cancers, often results in rapid tumor growth, early metastasis, and acquired therapeutic resistance. The POU class 2 homeobox...
7.
Tsuboyama N, Szczepanski A, Zhao Z, Wang L
Genome Biol
. 2022 Sep;
23(1):206.
PMID: 36180891
Background: BRCA1-associated protein 1 (BAP1) is an ubiquitin carboxy-terminal hydrolase, which forms a multi-protein complex with different epigenetic factors, such as ASXL1-3 and FOXK1/2. At the chromatin level, BAP1 catalyzes...
8.
Tsuboyama N, Wang R, Szczepanski A, Chen H, Zhao Z, Shi L, et al.
Oncogene
. 2022 Feb;
41(15):2152-2162.
PMID: 35194152
Small cell lung cancer (SCLC) is an aggressive disease, with patients diagnosed with either early-stage, limited stage, or extensive stage of SCLC tumor progression. Discovering and targeting the functional biomarkers...
9.
Zhao Z, Szczepanski A, Tsuboyama N, Abdala-Valencia H, Goo Y, Singer B, et al.
Cancer Res
. 2021 Aug;
81(18):4696-4708.
PMID: 34341073
Abnormalities in genetic and epigenetic modifications can lead to drastic changes in gene expression profiles that are associated with various cancer types. Small cell lung cancer (SCLC) is an aggressive...